Drug Trial Radar · NCT07884877
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
38
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Oct 2028
Study completion Oct 2030
Sponsor
- Lead sponsor
- Samsung Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma (liver cancer). It will also learn about the safety of this combination. The main questions it aims to answer are: * What percentage of participants are alive without cancer progression 12 months after starting PULSAR? * What medical problems do participants have after PULSAR with immunotherapy? There is no comparison group. Results will be compared with published results of immunotherapy alone. Participants will: * Continue their usual immunotherapy * Receive 2 to 3 PULSAR sessions, 3 to 4 weeks apart, with the plan adjusted before each session * Give blood samples and fill out symptom questionnaires * Have checkups and scans for up to 3 years
Conditions
- Hepatocellular Carcinoma (HCC)
- Radiotherapy-Induced Immune Priming
- Immunotherapy
Interventions
PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy)Radiation
Stereotactic radiotherapy (photon or proton), 8-12 Gy per pulse, 2-3 pulses at 3- to 4-week intervals, delivered between immunotherapy cycles. CT-based adaptive re-planning is performed before each pulse, with target volume reduced according to tumor response.
Immune checkpoint inhibitor-based therapyDrug
Standard-of-care immune checkpoint inhibitor-based systemic therapy chosen by the treating physician. Not provided by the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-Month Progression-Free Survival RateTime frame: 12 months from start of radiotherapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung medical center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.